Last reviewed 2026-06-03 · How we verify

BUCUMOLOL

Phase 2 active Small molecule ✓ Verified Jun 2026

BUCUMOLOL is a bucumolol drug. It is currently in Phase 2 development.

BUCUMOLOL is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

BUCUMOLOL is a small molecule drug in the bucumolol class, but its target and mechanism of action are unknown. Its commercial status, including whether it is patented or generic, and its approved indications are also unclear. The drug's half-life, bioavailability, and generic manufacturers are not publicly available. Further research is needed to understand its clinical use and safety profile. As a result, BUCUMOLOL is not a well-characterized drug.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	BUCUMOLOL
Drug class	bucumolol
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells have locks on them, and BUCUMOLOL is a key that fits into one of those locks. When it binds, it can affect how the cell works, but we don't know which lock it fits into or how it affects the cell's behavior. This is a simplified way of thinking about how BUCUMOLOL might work, but more research is needed to understand its actual mechanism.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BUCUMOLOL CI brief — competitive landscape report
BUCUMOLOL updates RSS · CI watch RSS

Frequently asked questions about BUCUMOLOL

What is BUCUMOLOL?

BUCUMOLOL is a bucumolol drug.

How does BUCUMOLOL work?

BUCUMOLOL is a small molecule that works by interacting with a specific target in the body, but its exact mechanism is unknown.

What drug class is BUCUMOLOL in?

BUCUMOLOL belongs to the bucumolol class. See all bucumolol drugs at /class/bucumolol.

What development phase is BUCUMOLOL in?

BUCUMOLOL is in Phase 2.

Drug class: All bucumolol drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing